Skip to content
Sign in

VRTX · NASDAQ

Vertex Pharmaceuticals (VRTX) Stock Price & Fundamentals

$582.14−0.35%−$2.03End-of-day price as of Oct 9, 2026

Vertex Pharmaceuticals (VRTX) closed at $582.14 on Oct 9, 2026, down 0.35% from the previous close of $584.17.

Share price, past year

1Y −7.84%

52-week range $568.80 – $660.42. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$582.14
Sep 30, 2026$579.31
Aug 31, 2026$610.76
Jul 31, 2026$595.50
Jun 30, 2026$644.96
May 29, 2026$612.20
Apr 30, 2026$609.43
Mar 31, 2026$612.76
Feb 27, 2026$628.48
Jan 30, 2026$653.39
Dec 31, 2025$627.13
Nov 28, 2025$634.06
Oct 31, 2025$632.94

Key statistics

Market cap
$147.48B
P/E (TTM)
33.9
EPS (TTM)
$17.17
Revenue (TTM)
$12.59B
Net income (TTM)
$4.41B
Shares outstanding
253.3M
Dividend yield
—
52-week range
$568.80 – $660.42

Vertex Pharmaceuticals's market cap is $147.48B, based on a share price of $582.14 and 253.3M shares outstanding as of Jun 30, 2026.

Financials

Vertex Pharmaceuticals reported revenue of $12.00B for fiscal 2025, up 8.90% from fiscal 2024.

Vertex Pharmaceuticals earned net income of $3.95B in fiscal 2025, a net margin of 32.9%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Vertex Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$12.00B+8.9%$3.95B32.9%$15.32$3.19B
FY2024ended Dec 31, 2024$11.02B+11.7%−$535.60M−4.9%−$2.08−$790.30M
FY2023ended Dec 31, 2023$9.87B+10.5%$3.62B36.7%$13.89$3.34B
FY2022ended Dec 31, 2022$8.93B+17.9%$3.32B37.2%$12.82$3.93B
FY2021ended Dec 31, 2021$7.57B+22.1%$2.34B30.9%$9.01$2.41B
FY2020ended Dec 31, 2020$6.21B+49.1%$2.71B43.7%$10.29$2.99B
FY2019ended Dec 31, 2019$4.16B+36.6%$1.18B28.3%$4.51$1.49B
FY2018ended Dec 31, 2018$3.05B+22.5%$2.10B68.8%$8.09$1.17B
FY2017ended Dec 31, 2017$2.49B+46.2%$263.48M10.6%$1.04$745.52M
FY2016ended Dec 31, 2016$1.70B—−$112.05M−6.6%−$0.46$179.54M
Vertex Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$3.33B$1.10B$4.31
Q1 FY2026ended Mar 31, 2026$2.99B$1.03B$4.02
Q4 FY2025ended Dec 31, 2025$3.19B$1.19B$4.64
Q3 FY2025ended Sep 30, 2025$3.08B$1.08B$4.20
Q2 FY2025ended Jun 30, 2025$2.96B$1.03B$3.99
Q1 FY2025ended Mar 31, 2025$2.77B$646.30M$2.49
Q4 FY2024ended Dec 31, 2024$2.91B$913.00M$3.62
Q3 FY2024ended Sep 30, 2024$2.77B$1.05B$4.01

Company profile

Name
Vertex Pharmaceuticals Incorporated
Ticker
VRTX
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
50 Northern Avenue, Boston, MA 02210
Incorporated in
MA
Fiscal year ends
December
SEC CIK
0000875320

Recent SEC filings

Frequently asked questions

What is Vertex Pharmaceuticals's stock price?

Vertex Pharmaceuticals (VRTX) closed at $582.14 on Oct 9, 2026, down 0.35% from the previous close of $584.17.

What is Vertex Pharmaceuticals's market cap?

Vertex Pharmaceuticals's market cap is $147.48B, based on a share price of $582.14 and 253.3M shares outstanding as of Jun 30, 2026.

How much revenue does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals reported revenue of $12.00B for fiscal 2025, up 8.90% from fiscal 2024.

What is VRTX's P/E ratio?

Vertex Pharmaceuticals's price-to-earnings ratio is 33.9, based on trailing twelve-month diluted EPS of $17.17.

Does Vertex Pharmaceuticals pay a dividend?

Vertex Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Vertex Pharmaceuticals Incorporated's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures